NGI-1-ML414-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemENGI-1Cat.No.:HY-117383CASNo.:790702-57-7Synonyms:ML414分?式:C??H??N?O?S?分?量:394.51作?靶點(diǎn):VirusProtease作?通路:Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(253.48mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.5348mL12.6740mL25.3479mL5mM0.5070mL2.5348mL5.0696mL10mM0.2535mL1.2674mL2.5348mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(6.34mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(6.34mM);ClearsolutionBIOLOGICALACTIVITY?物活性NGI-1(ML414)?種有效的寡糖轉(zhuǎn)移酶(OST)抑制劑，直接靶向和阻斷OST催化亞STT3A和STT3B的功能。NGI-1?種細(xì)胞滲透性抑制劑，可有效降低病毒感染性?不響細(xì)胞活?。IC50&TargetOST[1]體外研究NGI-1inhibitstheglycosylationofLASVGPmediatedbySTT3A-OST(inSTT3B-andMAGT1-TUSC3-cells)orSTT3B-OST(inSTT3A-cells)andimpairesitsproteolyticcleavageinadose-dependentmanner[1].NGI-1blocksEGFRN-linkedglycosylationinlungadenocarcinomacellsasassessed.IncontrolsEGFRisbiotinylated,consistentwithitsplasmamembraneexpression,butinNGI-1treatedcellstheEGFRispredominantlyfoundinthenon-biotinylatedintracellularfractionsuggestingachangeincellularlocalization[2].WesternBlotAnalysis[1]CellLine:STT3A-,STT3B-andMAGT1-TUSC3-cellsConcentration:1,2,5μMIncubationTime:36hoursResult:InhibitedtheglycosylationofLASVGPmediatedbySTT3A-OST(inSTT3B-andMAGT1-TUSC3-cells)orSTT3B-OST(inSTT3A-cells)andimpaireditsproteolyticcleavageinadose-dependentmanner.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CancerDiscov.2020Dec;10(12):1872-1893.?JVirol.2019Nov13;93(23):e01443-19.?FrontMolBiosci.2022Apr27;9:899192.?BiochemBiophResCo.2020Nov26;533(1):77-82.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ZhuS,etal.ComprehensiveInteractomeAnalysisRevealsthatSTT3BisRequiredfortheN-GlycosylationofLassaVirusGlycoprotein.JVirol.2019Sep11.pii:JVI.01443-19.[2].Lopez-SambrooksC,etal.OligosaccharyltransferaseinhibitioninducessenescenceinRTK-driventumorcells.NatChemBiol.20162/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEDec;12(12):1023-1030.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalappli